Theralase Technologies Inc. Asset Resilience Ratio
Theralase Technologies Inc. asset resilience ratio. Theralase Technologies Inc. (TLT) has an Asset Resilience Ratio of 5.90% as of September 2006. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TLT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Theralase Technologies Inc. (2004–2005)
Asset resilience ratio of Theralase Technologies Inc. from 2004 to 2005. This chart shows how Theralase Technologies Inc.'s Asset Resilience Ratio has changed over time. Read TLT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Theralase Technologies Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Theralase Technologies Inc.'s balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$219.63K | 5.9% |
| Total Liquid Assets | CA$219.63K | 5.90% |
Asset Resilience Insights
- Limited Liquidity: Theralase Technologies Inc. maintains only 5.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Theralase Technologies Inc. Industry Peers by Asset Resilience Ratio
Compare Theralase Technologies Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Theralase Technologies Inc. Asset Resilience Ratio by Year (2004–2005)
Theralase Technologies Inc. asset resilience ratio by year from 2004 to 2005. The table below shows the annual Asset Resilience Ratio data for Theralase Technologies Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2005-12-31 | 8.86% | CA$314.50K ≈ $227.51K |
CA$3.55 Million ≈ $2.57 Million |
-23.98pp |
| 2004-12-31 | 32.84% | CA$399.01K ≈ $288.64K |
CA$1.22 Million ≈ $878.97K |
-- |
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form … Read more